Berkan Kurt: Inflammatory Biomarkers in Heart Failure
Berkan Kurt, Resident Physician in Cardiology and Internal Medicine at Uniklinik RWTH Aachen, reposted from Florian Kahles, on LinkedIn:
“In our new review, we look at heart failure with a focus on chronic low-grade inflammation, discuss how hsCRP, IL-6 and other biomarkers capture residual inflammatory risk in HFpEF and HFrEF and may help guide future anti-inflammatory strategies.
Also excited to share that this is the first publication of our MD student Konstantin Rex, who co-led the work. ”
Quoting Florian Kahles’s post:
“Happy to share our new review in Current Heart Failure Reports, “Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates.”
We summarize how low-grade systemic inflammation drives HF pathobiology and outline the complementary roles of hsCRP as a practical risk marker and IL-6 as a causal pathway with therapeutic potential.
We also discuss implications for risk stratification, precision medicine, and ongoing IL-6–targeted trials in HF.”
Read the full article here.
Article: Inflammatory Biomarkers in Heart Failure: Clinical Perspectives on hsCRP, IL-6 and Emerging Candidates
Authors: Berkan Kurt, Konstantin Rex, Martin Reugels, Christopher B. Fordyce, Marat Fudim, Abhinav Sharma, Martin Berger, Nikolaus Marx, Katharina Marx-Schütt, Florian Kahles
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor
-
Jan 16, 2026, 04:51Higher-Dose Clotting Factor Prophylaxis Does Not Reduce Postpartum Hemorrhage in Women with von Willebrand Disease
-
Jan 16, 2026, 04:48Reza Shojaei on Plasma Donation as Life-Changing Medicine in Motion
-
Jan 16, 2026, 04:11Open-Label Extension Study of Marstacimab: Pfizer Has Reported a Fatal Event
-
Jan 16, 2026, 04:11Why is DVT More Common In the Left Leg? Dr Raheel Moazzam’s New Study Gives Answers!